Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models
A complete resection of tongue cancer is often difficult. We investigate the usefulness of administering G47Δ (teserpaturev), a triple-mutated oncolytic herpes simplex virus type 1, prior to resection. G47Δ exhibits good cytopathic effects and replication capabilities in all head and neck cancer cel...
Main Authors: | Kosuke Inoue, Hirotaka Ito, Miwako Iwai, Minoru Tanaka, Yoshiyuki Mori, Tomoki Todo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770523000487 |
Similar Items
-
Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors
by: Tomoharu Yamada, et al.
Published: (2023-03-01) -
Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
by: Mingming Hu, et al.
Published: (2023-11-01) -
Corrigendum: Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
by: Mingming Hu, et al.
Published: (2023-12-01) -
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma
by: Lushun Chalise, et al.
Published: (2022-09-01) -
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
by: Masmudur M. Rahman, et al.
Published: (2021-10-01)